YF 476

gastrin ; Homo sapiens

12 Article(s)
Pub. Year
#Total Relationships
1 33782049 Randomized Controlled Trial of the Gastrin/CCK2 Receptor Antagonist Netazepide in Patients with Barrett's Esophagus. 2021 Jun 2
2 27704617 Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis. 2017 Mar 2
3 27796466 Randomised trial of the effect of a gastrin/CCK2 receptor antagonist on esomeprazole-induced hypergastrinaemia: evidence against rebound hyperacidity. 2017 Feb 4
4 25665655 Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist. 2015 May 2
5 24279703 The regulation of gastric acid secretion - clinical perspectives. 2014 Feb 1
6 23179899 The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression. 2013 Jan 2
7 23432415 Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24 h gastric acidity and gastrin in healthy subjects. 2013 Nov 2
8 23432534 Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects. 2013 Nov 5
9 24098507 Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis. 2013 4
10 22607579 Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. 2012 Jul 2
11 23072686 Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. 2012 Dec 1
12 9042983 YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo. 1997 Feb 1